NNVC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NanoViricides, Inc (NNVC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has weak technical indicators, and its financial performance is not encouraging. While there is a positive analyst rating with a high price target, the lack of recent news, congress trading activity, and proprietary trading signals suggests that this is not an optimal entry point for a long-term investment.
The technical indicators for NNVC are bearish. The MACD is below zero and negatively expanding, the RSI is neutral at 34.523, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 0.934 and S2 at 0.9, suggesting further downside risk.
Alliance Global analyst James Molloy initiated coverage with a Buy rating and a $6 price target, citing potential for significant opportunity if NV-387 performs well in Phase 2 trials.
No significant trading trends from hedge funds or insiders. No recent news or congress trading data. Financial performance shows stagnant revenue, negative net income, and declining EPS. Technical indicators are bearish.
In Q2 2026, revenue remained at 0 with no growth. Net income improved slightly by 9.53% YoY but remains negative at -$2,220,719. EPS dropped by 21.43% YoY to -0.11. Gross margin remains at 0, indicating no profitability.
Alliance Global analyst James Molloy initiated a Buy rating with a $6 price target, citing potential for significant opportunity if NV-387 performs well in Phase 2 trials. However, there is no consensus or additional analyst coverage to support this view.
